Catheter Precision, Inc. Completes Enrollment Of 75 Patients In Its LockeT-II Study, Which Is Expected To Conclude In Oct. 2024
Portfolio Pulse from Benzinga Newsdesk
Catheter Precision, Inc. has completed the enrollment of 75 patients in its LockeT-II study, which is expected to conclude in October 2024.
July 25, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Catheter Precision, Inc. (VTAK) has completed the enrollment of 75 patients in its LockeT-II study, which is expected to conclude in October 2024. This milestone indicates progress in their clinical trials, potentially boosting investor confidence.
The completion of patient enrollment in the LockeT-II study is a significant milestone for Catheter Precision, Inc. (VTAK). This progress in their clinical trials could boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100